CJC-1295 & Ipamorelin: Mimicking the Natural Pulse

The synergy problem

Growth hormone release from the pituitary is naturally pulsatile — roughly 5–7 peaks per 24 hours, with the largest occurring during slow-wave sleep. This pulsatility matters: continuous GH exposure produces different hepatic gene expression patterns than pulsatile exposure, with measurable consequences for IGF-1 generation, sex-specific cytochrome P450 induction, and metabolic effects in research models.

Directly administering exogenous GH abolishes pulsatility. Secretagogues preserve it. The CJC-1295 + Ipamorelin combination has become a standard research tool because it drives stronger GH pulses than either compound alone — through two mechanistically distinct receptor pathways working together.

Two receptors, one pulse

CJC-1295 (no DAC) — a modified GHRH(1-29) analog with DPP-4 resistance and ~30-minute plasma half-life. It binds GHRH receptor (GHRHR) on somatotrophs, a class B GPCR coupled to Gαs. Action:

• Elevates cAMP in somatotrophs
• Amplifies basal GH-releasing signal
• Effect: primes the pituitary for a larger GH pulse

Ipamorelin — a selective ghrelin receptor agonist, 5-aa synthetic peptide. It binds GHS-R1a on somatotrophs, a class A GPCR coupled primarily to Gαq/11. Action:

• Elevates intracellular calcium via PLC/IP3
• Triggers GH vesicle exocytosis
• Effect: initiates the GH pulse

Why the combination works

The two receptors drive GH release through independent second-messenger pathways — cAMP and calcium. When activated simultaneously, the pathways converge on GH exocytosis with more than additive effect in published studies. This is classic synergy in GPCR pharmacology.

Separately:

• CJC-1295 alone → modest GH pulse (amplification without ignition)
• Ipamorelin alone → modest GH pulse (ignition without priming)
• CJC-1295 + Ipamorelin → substantially larger pulse than sum of individual effects

Why ipamorelin specifically

Earlier ghrelin-receptor agonists (GHRP-6, GHRP-2) activate GHS-R1a but also stimulate:

• Prolactin release — particularly GHRP-6
• ACTH / cortisol elevation — all GHRP generations to varying degrees
• Hunger / appetite — GHRP-6 strongly, GHRP-2 moderately

Ipamorelin was engineered for GH selectivity — it produces GH release comparable to GHRP-6 but with minimal prolactin and cortisol stimulation, making it the cleanest experimental tool for isolating GH-pulse pharmacology.

What laboratories typically study

• Pituitary cell culture — primary somatotroph and pituitary-derived line GH release
• Pulse pharmacology — in vivo GH time-course measurements in rodent models
• IGF-1 generation — downstream hepatic response to sustained vs pulsatile GH
• Tachyphylaxis — receptor desensitization kinetics with repeated administration
• Receptor cross-talk — bias and coupling studies between GHRHR and GHS-R1a
• Body composition studies — in DIO and aged rodent models, measuring lean/fat mass shifts
• Sleep architecture — GH pulse contribution to slow-wave sleep physiology

Handling and quality

Both compounds are supplied as lyophilized powder.

• CJC-1295 no-DAC: 5 mg typical format; store -20°C
• Ipamorelin: 5 mg typical format; store -20°C
• Reconstitute each in sterile/bacteriostatic water separately before combination in dose-loading
• Reconstituted stability ~4 weeks at 2–8°C
• Verify purity by HPLC (≥99.0%) with MS identity; request batch COA

Combinations require institutional justification. We do not publish protocols.

Related reading

• /research/cjc-1295-no-dac — compound profile
• /research/ipamorelin — compound profile
• /compare/ipamorelin-vs-cjc-1295 — class comparison
• /blog/sermorelin-vs-cjc-1295-ghrh-analog-research — GHRH class
• /blog/ghrp-6-ghrp-2-ipamorelin-growth-hormone-secretagogue-research — ghrelin-receptor class
• /blog/cjc-1295-dac-vs-no-dac-research-design — DAC vs no-DAC
• /category/muscle-growth-research — broader category

RUO disclaimer

For laboratory research use only. Not for human consumption. Combinations require institutional justification and oversight.